Opko Health to Buy Bio-Reference Labs for $1.47B | GenomeWeb

NEW YORK (GenomeWeb) – Opko Health and Bio-Reference Laboratories today announced a definitive merger agreement valued at about $1.47 billion. 

Under the terms of the deal, each Bio-Reference shareholder will receive 2.75 shares of Opko's common stock for each share of Bio-Reference stock. Based on Opko's closing price of $19.12 per share on June 3, the transaction is estimated to be worth $52.58 per share of Bio-Reference's common stock, the firms said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Sponsored by

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.